TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS
Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating fibrosis
-
Paragraph 00249
(2020/11/30)
COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS
Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.
-
Paragraph 00273
(2020/12/01)
SUBSTITUTED ALKOXYPYRIDINYL INDOLSULFONAMIDES
The present application relates to alkoxy-substituted pyridinyl indolsulfonamides. The compounds are negative GPR17 modulators and have utility in the treatment of various GPR17 associated disorders.
-
(2020/01/08)
IRE1 SMALL MOLECULE INHIBITORS
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
-
Paragraph 00309
(2019/05/30)
(AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES
Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
-
(2018/07/29)
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
-
Paragraph 1026
(2017/05/14)
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
-
Paragraph 0742
(2015/08/03)
CHEMICAL COMPOUNDS
The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a
-
Page/Page column 117
(2010/11/28)
More Articles about upstream products of 944799-22-8